Back

Transcriptomic Integration Reveals a Conserved Inflammatory--Proliferative Paradox in Acquired Resistance to Immune Checkpoint Blockade

Lee, H.; Yeo, H.; Bak, I.; Yoo, K.-W.; Park, S.-M.

2026-04-05 bioinformatics
10.64898/2026.04.01.714095 bioRxiv
Show abstract

Acquired resistance to immune checkpoint blockade (ICB) is increasingly recognized as an active adaptive process. However, prior studies have typically focused on individual tumor models, limiting the ability to distinguish conserved mechanisms from model-specific observations. Here, we integrated four independent transcriptomic datasets of acquired ICB resistance, spanning human non-small cell lung cancer (NSCLC) biopsies, murine CT26 colorectal tumors, organoid-derived murine NSCLC tumors, and EMT6 breast cancer cells. Differential expression analysis was performed within each dataset, followed by an intersection-based consensus approach to identify reproducible resistance-associated programs. Contrary to the conventional cold tumor paradigm, acquired-resistance tumors consistently maintained interferon-{gamma} response and innate immune signaling while simultaneously activating cell-cycle programs and constitutive KRAS signaling signatures across all four models. We term this an apparent inflammatory-proliferative paradox: the persistence of IFN-{gamma}-driven inflammatory signatures, canonically associated with productive antitumor immunity, in tumors that have escaped immune control. Notably, this program was retained in immune-depleted organoid and cell-line models, supporting a tumor-cell-associated component maintained independently of the immediate immune microenvironment. Transcription factor activity inference identified a conserved regulatory backbone linking interferon-associated regulators (STAT2, IRF2) with proliferation drivers (E2F4, TFDP1) and suppression of lineage-specifying factors (HNF4A, EGR1). Integrated network analysis resolved these signals into three reinforcing modules, namely hyper-proliferative outgrowth, active inflammatory adaptation, and lineage identity loss. This architecture provides a systems-level framework for prioritizing combination strategies that simultaneously address interconnected resistance axes.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Cell Systems
167 papers in training set
Top 0.3%
19.7%
2
Nature Communications
4913 papers in training set
Top 5%
19.0%
3
Cell Reports
1338 papers in training set
Top 3%
9.3%
4
Science Immunology
81 papers in training set
Top 0.1%
8.5%
50% of probability mass above
5
JCI Insight
241 papers in training set
Top 2%
3.3%
6
eLife
5422 papers in training set
Top 29%
3.1%
7
Cell Genomics
162 papers in training set
Top 2%
2.1%
8
Nucleic Acids Research
1128 papers in training set
Top 8%
2.1%
9
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 29%
1.9%
10
Nature Cell Biology
99 papers in training set
Top 2%
1.9%
11
Cancer Cell
38 papers in training set
Top 0.9%
1.7%
12
Molecular Cell
308 papers in training set
Top 7%
1.5%
13
Frontiers in Immunology
586 papers in training set
Top 5%
1.5%
14
Immunity
58 papers in training set
Top 3%
1.2%
15
Science Advances
1098 papers in training set
Top 23%
1.2%
16
EMBO reports
136 papers in training set
Top 4%
1.1%
17
Nature Genetics
240 papers in training set
Top 6%
1.1%
18
Cell Reports Medicine
140 papers in training set
Top 6%
0.9%
19
Nature Immunology
71 papers in training set
Top 2%
0.9%
20
Cancer Research
116 papers in training set
Top 3%
0.9%
21
Nature Biotechnology
147 papers in training set
Top 7%
0.8%
22
Nature Metabolism
56 papers in training set
Top 2%
0.8%
23
Advanced Science
249 papers in training set
Top 17%
0.8%
24
Genome Medicine
154 papers in training set
Top 8%
0.8%
25
Cell
370 papers in training set
Top 17%
0.8%
26
Cancer Research Communications
46 papers in training set
Top 2%
0.5%
27
Nature Microbiology
133 papers in training set
Top 5%
0.5%
28
iScience
1063 papers in training set
Top 40%
0.5%
29
Scientific Reports
3102 papers in training set
Top 80%
0.5%
30
Cancer Discovery
61 papers in training set
Top 2%
0.5%